Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Observational Database Evaluating Outcomes of Using Carbetocin (Duratocin®) as the Primary Uterotonic Following Cesarean Delivery at Maisonneuve-Rosemont Hospital

NCT03959436 is registered in ClinicalTrials.gov with Maisonneuve-Rosemont Hospital as lead sponsor.

NCT NCT03959436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03959436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Observational Database Evaluating Outcomes of Using Carbetocin (Duratocin®) as the Primary Uterotonic Following Cesarean Delivery at Maisonneuve-Rosemont Hospital
Lead sponsor
Maisonneuve-Rosemont Hospital
Phase
Observational
Overall status
Completed
Start date
March 29, 2017
Completion date
March 16, 2018
Enrollment
612 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carbetocin, cesarean section complications, uterine atony with hemorrhage, uterotonics